Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “NSCLC Adenocarcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02697591
What this trial is testing

INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced MalignanciesMetastatic Cancer
Incyte Biosciences International Sàrl 100
Not applicableLooking for participantsNCT06605404
What this trial is testing

Pan-tumor MRD Study

Who this might be right for
Muscle Invasive Bladder Urothelial CarcinomaEsophageal CancerGastric and Gastroesophageal Junction (GEJ) Adenocarcinoma+4 more
Paradigm Health 1,350
Early research (Phase 1)Study completedNCT01131234
What this trial is testing

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Who this might be right for
Adult Anaplastic AstrocytomaAdult Anaplastic EpendymomaAdult Anaplastic Oligodendroglioma+49 more
National Cancer Institute (NCI) 20
Not applicableLooking for participantsNCT07374614
What this trial is testing

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Who this might be right for
Non-Small Cell Lung CancerALKIruplinalkib+3 more
Peking University Shenzhen Hospital 20
Early research (Phase 1)Not Yet RecruitingNCT07583771
What this trial is testing

A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma

Who this might be right for
Pancreatic AdenocarcinomaNon Small Cell Lung CancerAdvanced Solid Tumors+2 more
Chipscreen Biosciences, Ltd. 186
Testing effectiveness (Phase 2)UnknownNCT02787447
What this trial is testing

Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy

Who this might be right for
Lung Adenocarcinoma
First People's Hospital of Hangzhou 46
Early research (Phase 1)Looking for participantsNCT04147078
What this trial is testing

Personalized DC Vaccine for Postoperative Cancer

Who this might be right for
Gastric CancerHepatocellular CarcinomaNon-Small-Cell Lung Cancer+1 more
Sichuan University 80
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Not applicableStudy completedNCT01827852
What this trial is testing

AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 1,107
Early research (Phase 1)Active Not RecruitingNCT03252938
What this trial is testing

Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors

Who this might be right for
Solid TumorsPeritoneal CarcinomatosisNSCLC Adenocarcinoma+1 more
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 83
Testing effectiveness (Phase 2)Study completedNCT00264433
What this trial is testing

The Safety and Effects of ADH-1 Given Intravenously as a Single Agent

Who this might be right for
Neoplasms
Adherex Technologies, Inc.
Not applicableNo Longer AvailableNCT03554434
What this trial is testing

An Expanded Access Program for AM0010 (Pegilodecakin)

Who this might be right for
MelanomaProstate CancerOvarian Cancer+6 more
Eli Lilly and Company
Early research (Phase 1)Ended earlyNCT03809624
What this trial is testing

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

Who this might be right for
Metastatic Solid TumorsNon-small Cell Lung CancerMelanoma+6 more
Inhibrx Biosciences, Inc 160
Not applicableEnrolling By InvitationNCT06885424
What this trial is testing

A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products

Who this might be right for
Solid Tumor CancerSolid Tumor, Unspecified, AdultColorectal Carcinoma+12 more
A2 Biotherapeutics Inc. 400
Not applicableEnded earlyNCT04436120
What this trial is testing

Treatment Resistance Following Anti-cancer Therapies

Who this might be right for
Disease Progression
Pfizer 38
Testing effectiveness (Phase 2)Study completedNCT04263090
What this trial is testing

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Who this might be right for
Non-small Cell Lung CancerAdenocarcinomaStage IV
Icahn School of Medicine at Mount Sinai 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04280081
What this trial is testing

Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation

Who this might be right for
Solid TumorMedullary Thyroid Cancer
Eli Lilly and Company 77
Large-scale testing (Phase 3)Study completedNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Early research (Phase 1)Study completedNCT04148937
What this trial is testing

The CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Who this might be right for
Advanced Cancer
Eli Lilly and Company 52
Early research (Phase 1)Ended earlyNCT02419495
What this trial is testing

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Who this might be right for
Advanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8+26 more
M.D. Anderson Cancer Center 221
Next Page